Dr. Robert Hoyer, MD
Claim this profileUCHealth Memorial Hospital Central
Studies Cancer
Studies Tumors
18 reported clinical trials
33 drugs studied
About Robert Hoyer, MD
Education:
- Received MD from the University of Colorado School of Medicine in 2008.
- Completed Residency in Internal Medicine at the University of Colorado School of Medicine in 2011.
- Finished Fellowship in Pulmonary and Critical Care Medicine at the University of Colorado School of Medicine in 2014.
Experience:
- Currently practices as a pulmonologist and critical care specialist at UCHealth Memorial Hospital Central.
Area of expertise
1Cancer
Stage IV
Stage III
HER2 positive
2Tumors
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Robert Hoyer, MD is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Metformin
for Prostate Cancer Patients with Glucose Intolerance or Overweight
Metformin is used widely in the treatment of type 2 diabetes. It has off-label indications for use in the prevention of diabetes and in hyperinsulinar obesity. In medical practices, the implementation of metformin for these off-label indications is variable, often at the level of the provider. Multiple retrospective investigations have also shown a clinical benefit in men with prostate cancer who are incidentally treated with metformin. This pragmatic study will test the feasibility of enrolling patients who have glucose intolerance (as defined by HbA1c of 5.7-6.4%) and/or who have increased BMI (BMI greater than or equal to 25 kg/m2) to a randomized pragmatic study of metformin plus lifestyle modification information versus lifestyle modification information only. For purposes of the scope of this project and the study's feasibility, this will be implemented in a group of prostate cancer patients, who may have additional benefits from metformin.
Recruiting0 awards Phase < 14 criteria
More about Robert Hoyer, MD
Clinical Trial Related4 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Robert Hoyer, MD has experience with
- Nivolumab
- Pembrolizumab
- Gemcitabine
- Abemaciclib
- Abiraterone
- Disitamab Vedotin
Breakdown of trials Robert Hoyer, MD has run
Cancer
Tumors
Colorectal Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert Hoyer, MD specialize in?
Robert Hoyer, MD focuses on Cancer and Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Robert Hoyer, MD currently recruiting for clinical trials?
Yes, Robert Hoyer, MD is currently recruiting for 6 clinical trials in Colorado Springs Colorado. If you're interested in participating, you should apply.
Are there any treatments that Robert Hoyer, MD has studied deeply?
Yes, Robert Hoyer, MD has studied treatments such as Nivolumab, Pembrolizumab, Gemcitabine.
What is the best way to schedule an appointment with Robert Hoyer, MD?
Apply for one of the trials that Robert Hoyer, MD is conducting.
What is the office address of Robert Hoyer, MD?
The office of Robert Hoyer, MD is located at: UCHealth Memorial Hospital Central, Colorado Springs, Colorado 80909 United States. This is the address for their practice at the UCHealth Memorial Hospital Central.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.